Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
Pharmabiz3d
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
SurvivorNet on MSN5d
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...
Novartis Pharma AG: FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
AOL16d
Breast cancer drug could help prolong survival for children with brain tumors, study finds
A drug called ribociclib, currently used to treat breast ... forms of brain cancer," says senior author Mariella Filbin, M.D., PhD, co-director of the Brain Tumor Center of Excellence at Dana ...
The American Journal of Managed Care23d
Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody. Data from the MARIPOSA study (NCT04487080) support this newest approval, and ...
ascopubs.org26d
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights
Fig 2. Summary of guideline recommendations. AEs, adverse events; CDK4/6, cyclin-dependent kinase 4/6; ESR1, estrogen receptor 2; ER, estrogen receptor; ET, endocrine ...